For decades, endometriosis has been underfunded, misunderstood, and undertreated. New science is changing that. Here is why the $220 billion endometriosis market represents one of the most compelling opportunities in medicine today.

A study by Sur180 Therapeutics, PHSU, and the Ponce Research Institute published in Biology of Reproduction demonstrates that blocking the CRHR1 receptor reduces endometriosis pain without compromising fertility, positioning Puerto Rico at the forefront of women’s health research.

Sur180 Therapeutics CEO Dr. Annelyn Torres-Reverón was featured on Notiséis WIPR, discussing the company’s mission and its novel non-hormonal approach to treating endometriosis.

Sur180 Therapeutics joined researchers from around the world at the SRI Annual Scientific Meeting in San Juan, Puerto Rico, sharing their science and advancing the conversation on endometriosis research.

Sur180 Therapeutics and Nura Health announce strategic partnership to advance endometriosis diagnostics and non-hormonal treatment.